Brokerages expect Assembly Biosciences Inc (NASDAQ:ASMB) to post earnings of ($0.78) per share for the current quarter, Zacks reports. Four analysts have provided estimates for Assembly Biosciences’ earnings. The highest EPS estimate is ($0.70) and the lowest is ($0.85). Assembly Biosciences reported earnings per share of ($0.96) in the same quarter last year, which indicates a positive year over year growth rate of 18.8%. The firm is scheduled to issue its next quarterly earnings results on Thursday, November 5th.
On average, analysts expect that Assembly Biosciences will report full year earnings of ($2.20) per share for the current financial year, with EPS estimates ranging from ($2.33) to ($2.07). For the next fiscal year, analysts forecast that the business will post earnings of ($3.40) per share, with EPS estimates ranging from ($3.85) to ($2.73). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Assembly Biosciences.
Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.19 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.22. Assembly Biosciences had a negative net margin of 136.24% and a negative return on equity of 30.14%. The firm had revenue of $39.38 million for the quarter, compared to the consensus estimate of $30.54 million.
ASMB traded up $0.20 during trading on Friday, hitting $15.62. 153,313 shares of the company’s stock were exchanged, compared to its average volume of 246,293. The business’s 50 day moving average is $17.49 and its two-hundred day moving average is $19.81. Assembly Biosciences has a fifty-two week low of $10.23 and a fifty-two week high of $27.84. The stock has a market cap of $513.20 million, a P/E ratio of -6.20 and a beta of 1.21.
Several hedge funds have recently made changes to their positions in the company. Two Sigma Advisers LP raised its holdings in shares of Assembly Biosciences by 20.1% in the second quarter. Two Sigma Advisers LP now owns 85,500 shares of the biopharmaceutical company’s stock valued at $1,994,000 after purchasing an additional 14,300 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Assembly Biosciences by 15.0% during the second quarter. Charles Schwab Investment Management Inc. now owns 211,076 shares of the biopharmaceutical company’s stock valued at $4,923,000 after buying an additional 27,605 shares during the period. AQR Capital Management LLC grew its position in Assembly Biosciences by 68.5% during the second quarter. AQR Capital Management LLC now owns 19,870 shares of the biopharmaceutical company’s stock valued at $463,000 after buying an additional 8,076 shares during the period. Engineers Gate Manager LP bought a new position in Assembly Biosciences during the second quarter valued at about $235,000. Finally, California State Teachers Retirement System grew its position in Assembly Biosciences by 7.1% during the second quarter. California State Teachers Retirement System now owns 46,271 shares of the biopharmaceutical company’s stock valued at $1,079,000 after buying an additional 3,083 shares during the period. Institutional investors own 91.23% of the company’s stock.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
Recommended Story: Pattern Day Trader
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.